Ramboll, US Corporation, USA.
Cox Associates, Colorado, USA.
Regul Toxicol Pharmacol. 2022 Jul;132:105185. doi: 10.1016/j.yrtph.2022.105185. Epub 2022 May 7.
The Steering Committee of the Alliance for Risk Assessment (ARA) opened a call for scientists interested in resolving what appeared to be a conundrum in estimating of the half-life of perfluorooctanoate (PFOA) in humans. An Advisory Committee was formed from nominations received and a subsequent invitation led to the development of three small independent working groups to review appropriate information and attempt a resolution. Initial findings were shared among these groups and a conclusion developed from the ensuing discussions. Many human observational studies have estimated the PFOA half-life. Most of these studies note the likely occurrence of unmonitored PFOA exposures, which could inflate values of the estimated PFOA half-life. Also, few of these studies estimated the half-life of PFOA isomers, the branched chains of which likely have shorter half-lives. This could deflate values of the estimated linear PFOA half-life. Fortunately, several studies informed both of these potential problems. The majority opinion of this international collaboration is that the studies striking the best balance in addressing some of these uncertainties indicate the likely central tendency of the human PFOA half-life is less than 2 years. The single best value appears to be the geometric mean (GM) of 1.3 years (Zhang et al., 2013, Table 3), based on a GM = 1.7 years in young females (n = 20) and GM = 1.2 years in males of all ages and older females (n = 66). However, a combined median value from Zhang et al. (2013) of 1.8 years also adds value to this range of central tendency. While the Collaboration found this study to be the least encumbered with unmonitored PFOA exposures and branched isomers, more studies of similar design would be valuable. Also valuable would be clarification around background exposures in other existing studies in case adjustments to half-life estimates are attempted.
风险评估联盟(ARA)指导委员会发布了一项招募对解决全氟辛酸(PFOA)在人体半衰期估计中似乎存在的难题感兴趣的科学家的呼吁。根据收到的提名,成立了一个顾问委员会,并随后发出邀请,成立了三个独立的小型工作组,以审查相关信息并尝试解决问题。最初的研究结果在这些小组之间共享,并根据随后的讨论得出结论。许多人类观察性研究都估计了 PFOA 的半衰期。这些研究大多指出可能存在未监测到的 PFOA 暴露,这可能会使估计的 PFOA 半衰期值膨胀。此外,这些研究中很少有人估计 PFOA 同分异构体的半衰期,其支链可能具有较短的半衰期。这可能会使估计的线性 PFOA 半衰期值缩小。幸运的是,有几项研究同时考虑了这两个潜在问题。这项国际合作的多数意见是,在解决这些不确定性方面做得最好的研究表明,人类 PFOA 半衰期的可能中心趋势不到 2 年。最准确的单一值似乎是 1.3 年的几何平均值(GM)(Zhang 等人,2013 年,表 3),这是基于年轻女性(n=20)的 GM=1.7 年和所有年龄段男性和老年女性(n=66)的 GM=1.2 年得出的。然而,Zhang 等人(2013 年)的综合中位数为 1.8 年,也为这一中心趋势范围增加了价值。虽然合作小组认为这项研究受未监测到的 PFOA 暴露和支链同分异构体的影响最小,但具有类似设计的更多研究将是有价值的。此外,如果试图调整半衰期估计值,那么澄清其他现有研究中的背景暴露情况也将是有价值的。